Products for Research Use Only
RegisterLogin

Doxifluridine

CAT: 0804-HY-B0021-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0021-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs[1][2][3].
CAS Number
3094-09-5
Product Name Alternative
Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Thymidylate Synthase
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Doxifluridine.html
Purity
99.91
Solubility
DMF : 100 mg/mL (ultrasonic) |DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic)
Smiles
O=C(N1)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C(F)C1=O
Molecular Formula
C9H11FN2O5
Molecular Weight
246.19
Precautions
H315, H319, H335
References & Citations
[1]Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011 Aug;102 (8) :1545-52.|[2] Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest. 1988;6 (4) :377-83. |[3]Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. Tumori. 1999 May-Jun;85 (3) :211-3.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
MBS3603989-01Doxifluridine
A11847-500Doxifluridine 500mg
TRC-D556752-25MGDoxifluridine-13C5

Popular Products